Tigecycline: clinical evidence and formulary positioning
- 31 March 2005
- journal article
- review article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 25 (3), 185-192
- https://doi.org/10.1016/j.ijantimicag.2004.11.006
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The Antibiotic Pipeline — Challenges, Costs, and ValuesNew England Journal of Medicine, 2004
- Medical Treatment of Diabetic Foot InfectionsClinical Infectious Diseases, 2004
- Linezolid Resistance in SequentialStaphylococcus aureusIsolates Associated with a T2500A Mutation in the 23S rRNA Gene and Loss of a Single Copy of rRNAThe Journal of Infectious Diseases, 2004
- Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram‐Positive Bacterial InfectionsClinical Infectious Diseases, 2004
- Hospital‐Acquired Infective Endocarditis: Should the Definition be Broadened?Clinical Infectious Diseases, 2004
- The GlycylcyclinesDrugs, 2004
- Antimicrobial Resistance Trends and Outbreak Frequency in United States HospitalsClinical Infectious Diseases, 2004
- The Impact of Antimicrobial Resistance on Health and Economic OutcomesClinical Infectious Diseases, 2003
- Appropriate Empirical Antibacterial Therapy for Nosocomial InfectionsDrugs, 2003
- Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial ResistanceMicrobiology and Molecular Biology Reviews, 2001